Shanghai Realbio Technology (RBT) Co., Ltd.,
Shanghai Realbio Technology (RBT) Co., Ltd., was established in 2014 and is headquartered in Shanghai Pujiang High-tech Park. It has established regional centers in Hangzhou, Qingdao, Beijing, Wuhan and other places. It is a national high-tech enterprise specializing in genetic technology and health services. The company has always been adhering to the corporate philosophy of "forge ahead", relying on strong technical strength, adhering to the mission of letting everyone enjoy a healthy life, creating beauty for health, creating miracles for life, and fulfilling the vision of human beings. Customers provide the highest quality products and services.Since its establishment, the company has established a high-quality comprehensive team from top universities at home and abroad, multidisciplinary and interdisciplinary, including many elites in genomics, medicine, bioinformatics and other fields, of which more than 60% have a master's degree or above. Relying on the high-throughput sequencing technology platform, the company focuses on the breakthroughs in basic scientific research in the cutting-edge technology and research results of the human microbiome, as well as the transformation and application in medicine. It has obtained more than 40 software copyrights and multiple patents. The team members have been Many articles have been published in international journals such as Nature, Science and Nature Genetics. Develop detection technologies and application solutions in precision medical fields such as early screening and diagnosis of colorectal cancer, and metagenomic detection of infectious microorganisms. It is committed to providing early disease detection and comprehensive health management services for medical institutions. It has reached depth with more than 300 top hospitals across the country. Cooperation.
The company has successively won many honorary titles such as "National High-tech Enterprise", "Shanghai Specialized and Special New Small and Medium-sized Enterprise", "Shanghai Minhang Top Ten Technology Entrepreneurship Enterprise", "Shanghai Top 50 Venture Enterprise with Most Investment Potential". Up to now, the company has successfully obtained four rounds of investment from well-known investment companies such as Lucion Venture Capital, Zhangjiang Hi-Tech, Marathon Venture Partners, Songhe Capital, etc. The cumulative financing amount has exceeded 200 million yuan.
Hangzhou Realgene Technology Co., Ltd.
Hangzhou Realgene Technology Co., Ltd. is located in the West Lake Science and Technology Park in Hangzhou City, Zhejiang Province. It is the R&D center of Realbio Technology Group. The company has domestic advanced supporting experimental equipment and a powerful biological information analysis platform, complete laboratory equipment, including MiniSeq sequencer, interrupter Biorupter, detection equipment Agilent2100, Qubit2.0 fluorometer, PCR instrument, electrophoresis, centrifuge, Gel imaging equipment, etc. In terms of information analysis platform construction, the company has a computer cluster suitable for massive biological information analysis, 20 computing nodes with 64G memory, 3 computing nodes with 1T large memory, 10 sets of high-performance storage, with a total storage space of 1.2PB, data center The computing power has reached 50T flops, and the node CPUs are all Intel Xeon series. The center is also equipped with a 10-Gigabit high-speed switching network, UPS uninterruptible power supply, etc. to ensure the normal and stable operation of the computing cluster.Qingdao Realbio Precision Medical Laboratory Co., Ltd.,
Qingdao Realbio Precision Medical Laboratory Co., Ltd., was registered in November 2017 and is located in the Qingdao International Economic Cooperation Zone (Sino-German Ecological Park) of Shandong Free Trade Zone. Qingdao Realbio Precision Medical Testing Center is a North China inspection service headquarters base carefully built by Realbio Technology Group. It has a medical institution license and the service scope covers the entire North China region. A medical inspection office with a technical review certificate for clinical gene amplification testing laboratories. In mid-February 2020, it passed the Inter-laboratory Quality Assessment of New Coronavirus Nucleic Acid Test by Shanghai Clinical Laboratory Center (CNAS PT0025) and Shanghai Clinical Laboratory Quality Control Center with a perfect score.-
2020
- January
- RIntroduce Zhangjiang Hi-Tech Strategic Investment
- February
- RBT passed the 2020 Shanghai New Coronavirus Nucleic Acid Test Quality Evaluation
- May
- RBT was selected as a list of companies that made outstanding contributions during the epidemic prevention and control period in Minhang District
- June
- RBT became a government-designated third-party new crown nucleic acid testing agency
- August
- RBT passed the 2020 Shandong New Coronavirus Nucleic Acid Test Quality Evaluation
- September
- CEO Nan Qin was elected as the editorial board member of the 5th Editorial Board of Chinese Journal of Microecology
-
2019
- April
- RBT joined the alliance of national digestive early cancer prevention and treatment center
- July
- RBT successfully passed the ISO9001 quality management system certification
- October
- RBT won the Outstanding Enterprise Award of the 8th China Innovation and Entrepreneurship Competition
- November
- RBT won the Best Technology Innovation Award in the Alibaba Maker Competition
- December
- RBT was shortlisted in the "Top 100 Future Medical Care in 2019-China Innovative Devices List"
-
2018
- May
- RBT won the honor of "Minhang Disrict Science and Technology Enterprise" of Shanghai in 2018
- June
- RBT participated in the 7th International Human Microbiome Congress
- July
- RBT successfully organized the 3rd Innovator’s Forum on Human Microbiome
- October
- Undertake 2018(2nd)Summit on Human Microbiome and Health
- December
- Completing A+ round of financing with investment of nearly 100 million yuan led by LUCION CAPITAL
- December
- RBT won the top5 of microorganism companies from "The top 100 healthcare companies of the future in 2018"
-
2017
- June
- RBT successfully organized the 2nd Innovator’s Forum on Human Microbiome
- July
- RBT co-founded the Chinese fecal bacteria library and a fecal bacteria transplantation (FMT) company - Yichang Medical Technology
- September
- RBT completed nearly 10 million US dollars of A Series of financing invested by Marathon Venture Partners
- October
- RBT launched the Chinese Gut Metagenomics Project
- November
- Colobaby™, a child intestinal microbiome screening product, was released
-
2016
- April
- RBT participated in the establishment of the Shandong Medical Laboratory, which won the title of “National Gene Detection Technology Application Demonstration Center”
- May
- RBT established an Agricultural Microbiome Company - Shenzhen Jinrui Biotechnology, Co., Ltd
- June
- RBT successfully organized the 1st Innovator’s Forum on Human Microbiome
- July
- Colohealth®, a gut microbiome detection product, entered the market
- August
- RBT set up a medical laboratory in Guizhou
- September
- RBT raised RMB 40 million ($5.9 million) in a pre-A Series financing round, which was led by Green Pine Capital Partners of Shenzhen
- October
- RBT participated in the 6th International Human Microbiome Congress
- November
- RBT was awarded the honor of "National High-tech Enterprise"
-
2015
- October
- The brand of REALMED was officially launched
- November
- COLOWELL®, the noninvasive early screening services for colorectal cancer, was successfully released
-
2014
- October
-
Realbio Technology (RBT) was established, and the brand of REALGENE was officially launched